October 1, 2009 – The six-month clinical outcome of Sahajanand Medical Technologies Supralimus Sirolimus-Eluting ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
October 01, 2009
September 30, 2009 – New clinical data released at TCT 2009 last week showed strong and sustained efficacy and ...
September 30, 2009
September 29, 2009 – Among the biggest news to come out of TCT 2009 last week was the late-breaking data from the ...
September 30, 2009September 29, 2009 – Cordis Corp. and Boston Scientific announced late today they reached an agreement to resolve ...
September 29, 2009September 29, 2009 – Elixir Medical Corp. last week at TCT 2009 announced positive results from three multicenter ...
September 29, 2009September 29, 2009 – Boston Scientific Corp. Sept. 25 announced two-year follow-up data from the HORIZONS-AMI ...
September 29, 2009
September 29, 2009 – At six months, patients receiving the NEVO Sirolimus-Eluting Coronary Stent reported ...
September 29, 2009September 21, 2009 — Boston Scientific Corp. today welcomed three-year results from the SPIRIT III clinical trial ...
September 22, 2009September 21, 2009 — Anticipating a change in the practice of interventional cardiology, Medtronic Inc. announced ...
September 22, 2009September 22, 2009 – Cordis Corp. has received approval from the U.S. Food and Drug Administration (FDA) for a new ...
September 22, 2009September 18, 2009 – Boston Scientific today said it completed patient enrollment in the workhorse portion of its ...
September 18, 2009
Feature | Dave Fornell
Bare metal stents (BMS) were introduced in 1994 as an improvement over balloon angioplasty alone, which had a high ...
September 17, 2009
September 18, 2009 ¬– Abbott has announced the company's schedule of key news announcements and events during the ...
September 17, 2009September 17, 2009 – Boston Scientific Corp. announced its schedule of the company's major events and press ...
September 17, 2009
September 17, 2009 – Elixir Medical Corp. said today its stent systems using bioabsorbable polymers will be ...
September 17, 2009© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now